Compare Neurocrine Biosciences Inc (NBIX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Procter & Gamble Co — how do they compare? Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B), while Procter & Gamble Co trades at $145.12 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 20.3× Neurocrine Biosciences Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PG | |
|---|---|---|
Market Cap | $16.76B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $167.18 |
52-Week Low | $123.10 | $138.10 |
Enterprise Value | $16.78B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding expectations, and a robust 18.44% net income margin. Recent news highlights its dividend reliability and supply chain improvements, while analyst consensus is bullish with a $161.20 price target.
Outlook remains positive due to steady profitability and dividend growth, but risks include premium valuation and economic sensitivity. Investors may find value in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
